Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

11034	Companies
241768	Keywords
170194	Articles
130148	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/11/2026 at 07:05, 10 days 2 hours ago

Biophytis Completes €5.3 Million Capital Increase to Fund Obesity Trial

Biophytis Capital Increase Clinical Study BIO101 Obesity Trial
REGULATED PRESS RELEASE

published on 09/11/2026 at 07:00, 10 days 2 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Biophytis completes €5.3 million capital increase to fund Phase 2 trial in obesity, balancing US and European investors. Proceeds target fat loss and muscle preservation with BIO101

Biophytis Capital Increase Phase 2 Trial BIO101 Obesity
BRIEF

published on 08/31/2026 at 07:05, 21 days 2 hours ago

Biophytis Strengthens Financial Position with Cash Runway into 2027

Biophytis Debt Reduction Financial Restructuring Clinical Studies Share Warrants
REGULATED PRESS RELEASE

published on 08/31/2026 at 07:00, 21 days 2 hours ago

Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Biophytis strengthens financial position, extends cash runway to Q1 2027. Cash inflows of €3.7M, debt reduction of over 30%. Phase 2 study in obesity in Q1 2027

Biophytis Financial Position Debt Reduction Obesity Study Cash Runway
PRESS RELEASE

published on 08/31/2026 at 06:59, 21 days 2 hours ago

Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Biophytis strengthens financial position and extends cash runway to Q1 2027 through new resources and debt reduction, starting Phase 2 obesity study in Q1 2027

Biophytis Financial Position Debt Reduction Phase 2 Study Cash Runway
BRIEF

published on 08/10/2026 at 07:05, 1 month 11 days ago

Biophytis Secures Approval for OBA Clinical Trial in Brazil

Biophytis Obesity Treatment BIO101 GLP-1 Therapies OBA Clinical Trial
REGULATED PRESS RELEASE

published on 08/10/2026 at 07:00, 1 month 11 days ago

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Biophytis secures approval from ANVISA for OBA clinical trial in Brazil, advancing BIO101 drug candidate for obesity treatment. Key milestone in multinational clinical development

Biophytis Obesity Treatment OBA Clinical Trial ANVISA Approval BIO101 Drug Candidate
BRIEF

published on 08/03/2026 at 07:05, 1 month 18 days ago

Biophytis Updates on Hong Kong Joint Venture Progress

Biophytis Joint Venture Clinical Trial Sarcopenia BIO101
REGULATED PRESS RELEASE

published on 08/03/2026 at 07:00, 1 month 18 days ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Biophytis provides an update on its Hong Kong joint venture, including intellectual property transfer, funding details, and clinical trial preparations

Biophytis Joint Venture Hong Kong Intellectual Property Clinical Trial
PRESS RELEASE

published on 08/03/2026 at 06:59, 1 month 18 days ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Biophytis provides an update on its Hong Kong joint venture, including key milestones achieved and imminent progress. The joint venture aims to develop BIO101 for sarcopenia in Asian markets

Biophytis Joint Venture Hong Kong Sarcopenia BIO101

Accesswire

Published on 09/19/2026 at 00:55, 2 days 8 hours ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 2 days 9 hours ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 2 days 11 hours ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 days 12 hours ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 2 days 18 hours ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/21/2026 at 09:00, 16 minutes ago

Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY
Published on 09/21/2026 at 09:00, 17 minutes ago

PAINTS AND CHEMICAL INDUSTRIES COMPANY S.A.E. - Removal
Published on 09/21/2026 at 09:00, 17 minutes ago

Official List Notice
Published on 09/21/2026 at 08:50, 26 minutes ago

Infrastructure Capital Advisors Celebrates Launch of S&P 500 Option Income UCITS ETF (SPYC)
Published on 09/21/2026 at 08:30, 46 minutes ago

ASMAX at CIMAMotor 2026: Rethinking What a Motorcycle Intercom Should Be

Les Echos

Published on 09/21/2026 at 07:00, 2 hours 17 minutes ago

Peugeot Invest takes a stake in Mérieux NutriSciences
Published on 09/18/2026 at 18:34, 2 days 14 hours ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 2 days 15 hours ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 2 days 15 hours ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 3 days 15 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany

View all LES ECHOS COMFI WIRE